Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846430 · ClinicalTrials.gov registry record · Phase 2
Medical Treatment of "High-Risk" Neurofibromas
A Phase 2 study, sponsored by Corewell Health West.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00846430 is a Phase 2 study that has completed, run by Corewell Health West. The registered enrollment target is 9 participants.
The verdict
NCT00846430, a Phase 2 study, has completed, sponsored by Corewell Health West.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
Patients with neurofibromatosis type 1 (NF1) commonly develop non-cancerous tumors called plexiform neurofibromas. These tumors can be defined as "high-risk" when they result in severe pain, physical disability, organ dysfunction and/or become life-threatening. Presently, there is no effective medical therapy to offer patients with "high-risk" plexiform neurofibromas, and surgery does not provide lasting help. This study will evaluate the effectiveness of two treatment combinations in patients with "high-risk" plexiform neurofibromas.
Interventions
- DRUG Celecoxib (Celebrex)
- DRUG Peg-Interferon alpha-2b
- DRUG Temozolomide (temodar)
- DRUG Vincristine Sulfate (Oncovin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-10 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00846430
The ClinicalTrials.gov registry entry for NCT00846430 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health West, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Celecoxib (Celebrex) is the first listed.
NCT00846430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00846430 about?
NCT00846430 is a clinical study titled "Medical Treatment of "High-Risk" Neurofibromas". Patients with neurofibromatosis type 1 (NF1) commonly develop non-cancerous tumors called plexiform neurofibromas. These tumors can be defined as "high-risk" when they result in severe pain, physical disability, organ dysfunction and/or become life-threatening. Presently, there is no effective medic...
What is the current status of trial NCT00846430?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2008-10. Estimated completion is 2017-05.
What interventions are being tested in trial NCT00846430?
The interventions under investigation include: Celecoxib (Celebrex) (DRUG), Peg-Interferon alpha-2b (DRUG), Temozolomide (temodar) (DRUG), Vincristine Sulfate (Oncovin) (DRUG).
Who is sponsoring clinical trial NCT00846430?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.